PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET. It impedes RET function, promoting autophagic breakdown of FLT3, and suppresses the PI3K and Ras/ERK pathways, contributing to its anti-leukemic effects. The compound's antitumor efficacy is demonstrated in both a mouse MV4-11 flank xenograft model (doses of 3 and 10 mg/kg; po) and an allogeneic xenograft mouse model (dose of 40 mg/kg; po) [1].

PLM-101（30 nM、100 nM）能够有效地抑制PI3K信号通路中AKT（phospho-S473）与p70S6K（phospho-T389）的磷酸化过程，同时也抑制Ras信号通路中MEK（phospho-S217/S221）与ERK（phospho-T202/Y204）的磷酸化作用[1]。